Literature DB >> 17987646

Psychometric attributes of the SCOPA-COG Brazilian version.

Francisco Javier Carod-Artal1, Pablo Martínez-Martin, Wladimir Kummer, Luciola da Silveira Ribeiro.   

Abstract

Cross-cultural adaptation and independent psychometric assessment of the Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-COG), Brazilian version was performed. Parkinson's disease (PD) patients were evaluated by means of the SCOPA-Motor scale, Hoehn and Yahr staging (HY), Clinical Impression of Severity Index-PD (CISI-PD), Parkinson Psychosis Rating Scale, and Hospital Anxiety and Depression Scale. Cognition was evaluated using the Mini-Mental State Examination (MMSE), Short Portable Mental Status Questionnaire (SPMSQ), and SCOPA-COG. The following attributes were explored: acceptability, scaling assumptions, reliability, precision, and construct validity. One hundred fifty-two patients were assessed (mean age, 63.2 years; disease duration, 7.8 years; median HY stage, 3). Mean SCOPA-COG and MMSE were 18.2 and 25.7, respectively. The internal consistency of the SCOPA-COG (Cronbach's alpha = 0.81; item-total correlation, 0.38-0.62) was satisfactory. While the intraclass correlation coefficient value was 0.80, weighted kappa ranged from 0.30 (dice task) to 0.72 (animal fluency task). The standard error of measurement value for the SCOPA-COG was 3.2, whereas the smallest real difference was 8.9. SCOPA-COG total scores significantly decreased as the HY stage increased (Kruskal-Wallis, P < 0.0001). Age, years of education, and PD duration (all, P < 0.001) were observed to have an independent, significant effect on the SCOPA-COG. The SCOPA-COG is a short, reliable, valid instrument that is sensitive to cognitive deficits specific to PD. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2008        PMID: 17987646     DOI: 10.1002/mds.21769

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Authors:  Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  Psychometric properties of the Italian version of the Scales for Outcomes in Parkinson's disease- Cognition (SCOPA-Cog).

Authors:  V Isella; C Mapelli; N Morielli; D De Gaspari; C Siri; G Pezzoli; A Antonini; M Poletti; U Bonuccelli; L Picchi; A Napolitano; M Vista; M Veglia; F Piamarta; F Grassi; I M Appollonio
Journal:  Funct Neurol       Date:  2013 Apr-May

3.  Neurologists' diagnostic accuracy of depression and cognitive problems in patients with parkinsonism.

Authors:  Angela E P Bouwmans; Wim E J Weber
Journal:  BMC Neurol       Date:  2012-06-15       Impact factor: 2.474

4.  Cognitive impairments in Parkinson's disease: Evidence from an Iranian population.

Authors:  Farzad Ashrafi; Alireza Zali; Hossein Pakdaman; Karim Johari
Journal:  Iran J Neurol       Date:  2012

5.  Comparison of the use of screening tools for evaluating cognitive impairment in patients with Parkinson's disease.

Authors:  Carlos Henrique Ferreira Camargo; Eduardo de Souza Tolentino; Augusto Bronzini; Marcelo de Araújo Ladeira; Ronilson Lima; Gustavo Leopold Schultz-Pereira; Marcelo Rezende Young-Blood
Journal:  Dement Neuropsychol       Date:  2016 Oct-Dec

6.  The impact of cognitive performance on quality of life in individuals with Parkinson's disease.

Authors:  Maira Rozenfeld Olchik; Annelise Ayres; Marcieli Ghisi; Artur Francisco Schumacher Schuh; Carlos Roberto Mello Rieder
Journal:  Dement Neuropsychol       Date:  2016 Oct-Dec

7.  Executive cognitive tests for the evaluation of patients with Parkinson's disease.

Authors:  Emmanuelle Silva Tavares Sobreira; Marina Ceres Silva Pena; José Humberto Silva Filho; Carolina Pinto Souza; Guiomar Nascimento Oliveira; Vitor Tumas; Francisco de Assis Carvalho do Vale
Journal:  Dement Neuropsychol       Date:  2008 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.